Overview
BLRX market data
Price History
BLRX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BLRX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In OctoberBenzinga · Jul 20, 2026, 11:07 AM
BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian CancerBenzinga · Jul 8, 2026, 11:15 AM
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsightGlobenewswire Inc · Jun 16, 2026, 5:15 PM
BioLineRx (BLRX) Q1 2026 Earnings TranscriptThe Motley Fool · May 29, 2026, 7:15 PM
BioLine Rx Q1 Sales $477.000K Beat $343.000K EstimateBenzinga · May 27, 2026, 11:02 AM
BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual MeetingBenzinga · May 22, 2026, 11:10 AM
BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal ModelsBenzinga · May 19, 2026, 10:30 PM
BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade GliomasBenzinga · May 19, 2026, 11:05 AM